Differential regulatory role of pituitary adenylate cyclase-activating polypeptide in the serum-transfer arthritis model

Arthritis and Rheumatology

Volumn 66, Issue 10, 2014, Pages 2739-2750

  Botz, Bálint ^a   Bölcskei, Kata ^a   Kereskai, Lászlõ ^a   Kovács, Miklõs ^b   Németh, Tamás ^b   Szigeti, Krisztián ^c   Horváth, Ildikõ ^c   Máthé, Domokos ^c   Kovács, Noémi ^d   Hashimoto, Hitoshi ^e   Reglödi, Dõra ^a   Szolcsányi, János ^a   Pintér, Erika ^a   Mõcsai, Attila ^b   Helyes, Zsuzsanna ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d CROmed Ltd   (Hungary)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INDOCYANINE GREEN; LUCIGENIN; LUMINOL; MYELOPEROXIDASE; SUPEROXIDE; ADCYAP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ARTICLE; BIOLUMINESCENCE; BLOOD VESSEL PERMEABILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EDEMA; ENZYME ACTIVITY; FEMALE; FLUORESCENCE; GRIP STRENGTH; HISTOPATHOLOGY; HYPERALGESIA; HYPEREMIA; HYPERPLASIA; IMMUNOCOMPETENT CELL; IN VIVO STUDY; JOINT SWELLING; MALE; MICRO-COMPUTED TOMOGRAPHY; MONONUCLEAR CELL; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUTROPHIL; NONHUMAN; OSTEOPHYTE; PLETHYSMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SENSORY NERVE CELL; SERUM; SYNOVIAL HYPERPLASIA; ANIMAL; EXPERIMENTAL ARTHRITIS; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PAIN MEASUREMENT; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ARTHRITIS, EXPERIMENTAL; HYPERALGESIA; INFLAMMATION; MICE; MICE, KNOCKOUT; PAIN MEASUREMENT; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SENSORY RECEPTOR CELLS; SEVERITY OF ILLNESS INDEX;

EID: 84908388227     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38772     Document Type: Article

References (50)

1. Levine JD, Moskowitz MA, Basbaum AI,. The contribution of neurogenic inflammation in experimental arthritis. J Immunol 1985; 135: 843-7.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
3. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P,. New therapies for treatment of rheumatoid arthritis [review]. Lancet 2007; 370: 1861-74.
4. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-74.
5. Laburthe M, Couvineau A, Tan V,. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology [review]. Peptides 2007; 28: 1631-9.
6. Kim Y, Lee BD, Kim O, Bae YS, Lee T, Suh PG, et al. Pituitary adenylate cyclase-activating polypeptide 27 is a functional ligand for formyl peptide receptor-like 1. J Immunol 2006; 176: 2969-75.
7. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery [review]. Pharmacol Rev 2009; 61: 283-357.
8. Ohsawa M, Brailoiu GC, Shiraki M, Dun NJ, Paul K, Tseng LF,. Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse. Pain 2002; 100: 27-34.
9. Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T, et al. Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 2004; 24: 7283-91.
10. Sandor K, Bolcskei K, McDougall JJ, Schuelert N, Reglodi D, Elekes K, et al. Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice. Pain 2009; 141: 143-50.
11. McDougall JJ, Watkins L, Li Z,. Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain 2006; 123: 98-105.
12. Warren JB, Larkin SW, Coughlan M, Kajekar R, Williams TJ,. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo. Br J Pharmacol 1992; 106: 331-4.
13. Svensjo E, Saraiva EM, Amendola RS, Barja-Fidalgo C, Bozza MT, Lerner EA, et al. Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway. Microvasc Res 2012; 83: 185-93.
14. Botz B, Imreh A, Sandor K, Elekes K, Szolcsanyi J, Reglodi D, et al. Role of pituitary adenylate-cyclase activating polypeptide and Tac1 gene derived tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions. Peptides 2013; 43: 105-12.
15. Pozo D, Delgado M, Martinez C, Gomariz RP, Guerrero JM, Calvo JR,. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochim Biophys Acta 1997; 1359: 250-62.
16. Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea M, et al. PACAP in immunity and inflammation [review]. Ann N Y Acad Sci 2003; 992: 141-57.
17. Le Y, Li B, Gong W, Shen W, Hu J, Dunlop NM, et al. Novel pathophysiological role of classical chemotactic peptide receptors and their communications with chemokine receptors. Immunol Rev 2000; 177: 185-94.
18. Schmidt-Choudhury A, Furuta GT, Galli SJ, Schmidt WE, Wershil BK,. Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Pept 1999; 82: 65-9.
19. Harfi I, D'Hondt S, Corazza F, Sariban E,. Regulation of human polymorphonuclear leukocytes functions by the neuropeptide pituitary adenylate cyclase-activating polypeptide after activation of MAPKs. J Immunol 2004; 173: 4154-63.
20. Kinhult J, Egesten A, Uddman R, Cardell LO,. PACAP enhances the expression of CD11b, CD66b and CD63 in human neutrophils. Peptides 2002; 23: 1735-9.
21. Tan YV, Abad C, Lopez R, Dong H, Liu S, Lee A, et al. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2009; 106: 2012-7.
22. El Zein N, Badran B, Sariban E,. VIP differentially activates β2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1. J Leukoc Biol 2008; 83: 972-81.
23. Ransjo M, Lie A, Mukohyama H, Lundberg P, Lerner UH,. Microisolated mouse osteoclasts express VIP-1 and PACAP receptors. Biochem Biophys Res Commun 2000; 274: 400-4.
24. Persson E, Lerner UH,. The neuropeptide VIP potentiates IL-6 production induced by proinflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1. Biochem Biophys Res Commun 2005; 335: 705-11.
25. Nagata A, Tanaka T, Minezawa A, Poyurovsky M, Mayama T, Suzuki S, et al. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells. J Cell Physiol 2009; 221: 75-83.
26. Kanno Y, Ishisaki A, Yoshida M, Nakajima K, Tokuda H, Numata O, et al. Adenylyl cyclase-cAMP system inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. Mol Cell Endocrinol 2005; 229: 75-82.
27. Lundberg P, Lundgren I, Mukohyama H, Lehenkari PP, Horton MA, Lerner UH,. Vasoactive intestinal peptide (VIP)/ pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. Endocrinology 2001; 142: 339-47.
28. Persson E, Lerner UH,. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. J Cell Biochem 2011; 112: 3732-41.
29. Juhasz T, Matta C, Katona E, Somogyi C, Takacs R, Gergely P, et al. Pituitary adenylate cyclase activating polypeptide (PACAP) signalling exerts chondrogenesis promoting and protecting effects: implication of calcineurin as a downstream target. PLoS One 2014; 9: e91541.
30. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D,. Organ-specific disease provoked by systemic autoimmunity. Cell 1996; 87: 811-22.
31. Asquith DL, Miller AM, McInnes IB, Liew FY,. Animal models of rheumatoid arthritis [review]. Eur J Immunol 2009; 39: 1991-2058.
32. Hashimoto H, Shintani H, Baba A,. New insights into the central PACAPergic system from the phenotypes of PACAP- and PACAP receptor-knockout mice [review]. Ann N Y Acad Sci 2006; 1070: 75-89.
33. Jakus Z, Simon E, Balazs B, Mocsai A,. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum 2010; 62: 1899-910.
34. Helyes Z, Szabo A, Nemeth J, Jakab B, Pinter E, Banvolgyi A, et al. Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. Arthritis Rheum 2004; 50: 1677-85.
35. Meier R, Krug C, Golovko D, Boddington S, Piontek G, Rudelius M, et al. Indocyanine green-enhanced imaging of antigen-induced arthritis with an integrated optical imaging/radiography system. Arthritis Rheum 2010; 62: 2322-7.
36. Werner SG, Langer HE, Ohrndorf S, Bahner M, Schott P, Schwenke C, et al. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis 2012; 71: 504-10.
37. Kirchherr AK, Briel A, Mader K,. Stabilization of indocyanine green by encapsulation within micellar systems. Mol Pharm 2009; 6: 480-91.
38. Kim TH, Chen Y, Mount CW, Gombotz WR, Li X, Pun SH,. Evaluation of temperature-sensitive, indocyanine green-encapsulating micelles for noninvasive near-infrared tumor imaging. Pharm Res 2010; 27: 1900-13.
39. Gross S, Gammon ST, Moss BL, Rauch D, Harding J, Heinecke JW, et al. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med 2009; 15: 455-61.
40. Tseng JC, Kung AL,. In vivo imaging of inflammatory phagocytes. Chem Biol 2012; 19: 1199-209.
41. 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 2009; 50: 920-6.
42. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M,. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009; 132: 16-25.
43. Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM,. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans. J Appl Physiol 2012; 113: 1512-8.
44. Svensjo E, Saraiva EM, Bozza MT, Oliveira SM, Lerner EA, Scharfstein J,. Salivary gland homogenates of Lutzomyia longipalpis and its vasodilatory peptide maxadilan cause plasma leakage via PAC1 receptor activation. J Vasc Res 2009; 46: 435-46.
45. Sandor K, Kormos V, Botz B, Imreh A, Bolcskei K, Gaszner B, et al. Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice. Neuropeptides 2010; 44: 363-71.
46. Schytz HW, Holst H, Arendt-Nielsen L, Olesen J, Ashina M,. Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. J Headache Pain 2010; 11: 309-16.
47. Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, et al. Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states. J Pain 2008; 9: 449-56.
48. Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M,. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol 2001; 167: 3182-9.
49. Hardy RS, Hulso C, Liu Y, Gasparini SJ, Fong-Yee C, Tu J, et al. Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation. Arthritis Res Ther 2013; 15: R24.
50. Kelchtermans H, Struyf S, De Klerck B, Mitera T, Alen M, Geboes L, et al. Protective role of IFN-γ in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. J Leukoc Biol 2007; 81: 1044-53.